Molecular target agents in adrenocortical carcinoma: rationale and difficulties in trial design

Matthias Kroiss, Marcus Quinkler, Werner K. Lutz, Bruno Allolio, Martin Fassnacht, Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma Clinical Endocrinology. ,vol. 75, pp. 585- 591 ,(2011) , 10.1111/J.1365-2265.2011.04214.X

Martin Fassnacht, Massimo Terzolo, Bruno Allolio, Eric Baudin, Harm Haak, Alfredo Berruti, Staffan Welin, Carmen Schade-Brittinger, André Lacroix, Barbara Jarzab, Halfdan Sorbye, David J Torpy, Vinzenz Stepan, David E Schteingart, Wiebke Arlt, Matthias Kroiss, Sophie Leboulleux, Paola Sperone, Anders Sundin, Ilse Hermsen, Stefanie Hahner, Holger S Willenberg, Antoine Tabarin, Marcus Quinkler, Christelle De La Fouchardière, Martin Schlumberger, Franco Mantero, Dirk Weismann, Felix Beuschlein, Hans Gelderblom, Hanneke Wilmink, Monica Sender, Maureen Edgerly, Werner Kenn, Tito Fojo, Hans-Helge Müller, Britt Skogseid, None, Combination Chemotherapy in Advanced Adrenocortical Carcinoma The New England Journal of Medicine. ,vol. 366, pp. 2189- 2197 ,(2012) , 10.1056/NEJMOA1200966

Patrick Adam, Stefanie Hahner, Martina Hartmann, Barbara Heinrich, Marcus Quinkler, Holger S Willenberg, Wolfgang Saeger, Silviu Sbiera, Sebastian Schmull, Hans-Ullrich Voelker, Philipp Ströbel, Bruno Allolio, Martin Fassnacht, Epidermal growth factor receptor in adrenocortical tumors: analysis of gene sequence, protein expression and correlation with clinical outcome Modern Pathology. ,vol. 23, pp. 1596- 1604 ,(2010) , 10.1038/MODPATHOL.2010.153

Marcus Quinkler, Stefanie Hahner, Sebastian Wortmann, Sarah Johanssen, Patrick Adam, Christian Ritte, Christian Strasburger, Bruno Allolio, Martin Fassnacht, Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine. The Journal of Clinical Endocrinology and Metabolism. ,vol. 93, pp. 2057- 2062 ,(2008) , 10.1210/JC.2007-2564

A Naing, P LoRusso, S Fu, D Hong, H X Chen, L A Doyle, A T Phan, M A Habra, R Kurzrock, Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma British Journal of Cancer. ,vol. 108, pp. 826- 830 ,(2013) , 10.1038/BJC.2013.46

Frank Worden, David Olmos, Donghua Yin, David Schteingart, Gretchen N. Batzel, M. Luisa Paccagnella, Johann S. de Bono, Antonio Gualberto, Gary D. Hammer, Paul Haluska, Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma Cancer Chemotherapy and Pharmacology. ,vol. 65, pp. 765- 773 ,(2010) , 10.1007/S00280-009-1083-9

Matthias Kroiss, Marcus Quinkler, Sarah Johanssen, Nielka P. van Erp, Nienke Lankheet, Alexander Pöllinger, Katharina Laubner, Christian J. Strasburger, Stefanie Hahner, Hans-Helge Müller, Bruno Allolio, Martin Fassnacht, Sunitinib in Refractory Adrenocortical Carcinoma: A Phase II, Single-Arm, Open-Label Trial The Journal of Clinical Endocrinology and Metabolism. ,vol. 97, pp. 3495- 3503 ,(2012) , 10.1210/JC.2012-1419

Sebastian Wortmann, Marcus Quinkler, Christian Ritter, Matthias Kroiss, Sarah Johanssen, Stefanie Hahner, Bruno Allolio, Martin Fassnacht, Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma European Journal of Endocrinology. ,vol. 162, pp. 349- 356 ,(2010) , 10.1530/EJE-09-0804

Alfredo Berruti, Paola Sperone, Anna Ferrero, Antonina Germano, Arianna Ardito, Adriano Massimiliano Priola, Silvia De Francia, Marco Volante, Fulvia Daffara, Daniele Generali, Sophie Leboulleux, Paola Perotti, Eric Baudin, Mauro Papotti, Massimo Terzolo, Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma European Journal of Endocrinology. ,vol. 166, pp. 451- 458 ,(2012) , 10.1530/EJE-11-0918

A. Berruti, E. Baudin, H. Gelderblom, H.R. Haak, F. Porpiglia, M. Fassnacht, G. Pentheroudakis, Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Annals of Oncology. ,vol. 23, pp. 131- 138 ,(2012) , 10.1093/ANNONC/MDS231